Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance

Solid tumours are highly refractory to immune checkpoint blockade (ICB) therapies due to the functional impairment of effector T cells and their inefficient trafficking to tumours. T-cell activation is negatively regulated by C-terminal Src kinase (CSK); however, the exact mechanism remains unknown....

Descripción completa

Detalles Bibliográficos
Autores principales: Sridaran, Dhivya, Chouhan, Surbhi, Mahajan, Kiran, Renganathan, Arun, Weimholt, Cody, Bhagwat, Shambhavi, Reimers, Melissa, Kim, Eric H., Thakur, Manish K., Saeed, Muhammad A., Pachynski, Russell K., Seeliger, Markus A., Miller, W. Todd, Feng, Felix Y., Mahajan, Nupam P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663509/
https://www.ncbi.nlm.nih.gov/pubmed/36376335
http://dx.doi.org/10.1038/s41467-022-34724-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663509/
https://www.ncbi.nlm.nih.gov/pubmed/36376335
http://dx.doi.org/10.1038/s41467-022-34724-5

Ejemplares similares